Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

NCT04166552 is registered in ClinicalTrials.gov with Emerald Health Pharmaceuticals as lead sponsor.

NCT NCT04166552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis
Lead sponsor
Emerald Health Pharmaceuticals
Phase
Phase 2
Overall status
Suspended
Start date
June 11, 2020
Completion date
October 31, 2024
Enrollment
36 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis